Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?

Classification and Regression Trees.

John Van Ryzin, Leo Breiman, Jerome H. Friedman et al. · Journal of the American Statistical Association · 1986 · 21K citations

Computing, Computer Science, Mathematics +13

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text

Medicine, Oncology, Breast Oncology +12

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text

Medicine, Oncology, Pathology +11

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Soonmyung Paik, Gong Tang, Steven Shak et al. · Journal of Clinical Oncology · 2006 · 2.6K citations

Medicine, Cancer Biology, Oncology +17

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

Jennet Harvey, Gary M. Clark, C. Kent Osborne et al. · Journal of Clinical Oncology · 1999 · 2.1K citations

Medicine, Endocrinology, Oncology +17